Introduction: Recombinant human activated protein C (rh-APC), which has both anticoagulant and anti-inflammatory properties, improves survival of patients with severe sepsis. is beneficial effect is especially apparent in patients with pneumococcal pneumonia. Earlier treatment with rh-APC in sepsis has been associated with a better therapeutic response as compared to later treatment. In a mouse model it was recently confirmed that recombinant murine (rm-)APC decreases coagulation activation and improves survival in pneumococcal pneumonia, however APC did not impact on the inflammatory response. e aim of this study was to determine the effect of APC treatment instigated early in infection on activation of coagulation and inflammation after induction of pneumococcal pneumonia. Methods: Mice were infected intranasally with viable S. pneumoniae. Mice were treated with rm-APC ( μg) or vehicle intraperitoneally  hours after infection and were sacrificed after  hours, after which blood and organs were harvested for determination of bacterial outgrowth, coagulation activation and inflammatory markers. Results: In this early treatment model, rm-APC treatment inhibited pulmonary and systemic activation of coagulation as reflected by lower levels of thrombinantithrombin complexes and D-dimer. Moreover, rm-APC reduced the levels of a large number of cytokines and chemokines in the lung. Conclusions: When administered early in pneumococcal pneumonia, rm-APC inhibits systemic and pulmonary activation of coagulation and moreover exerts various anti-inflammatory effects in the lung.
Introduction
Community-acquired pneumonia (CAP) is a frequent cause of sepsis: in a recent sepsis trial . of the patients suffered from severe CAP, with S. pneumoniae as the most frequently isolated causative pathogen
 . An estimated . instances of pneumococcal pneumonia occur annually in the United States, including . hospitalized cases (Center for Disease Control and Prevention, U.S. Department of Health and Human Services (). Epidemiology and Prevention of VaccinePreventable Diseases, National Immunization Program) . Worldwide S. pneumoniae is responsible for approximately ten million deaths annually, which further points to pneumococcal pneumonia and sepsis as a major health threat  . e rise in antibiotic resistance of this pathogen urges further efforts to expand our therapeutic arsenal for pneumococcal pneumonia and sepsis  . Severe bacterial infection is associated with activation of coagulation and downregulation of anticoagulant mechanisms and fibrinolysis in the circulation  . In patients with bacterial pneumonia similar hemostatic changes have been demonstrated in the pulmonary compartment - . Among naturally occurring anticoagulant mechanisms, the protein C (PC) system prominently features as a regulator of both coagulation and inflammation. e end product of this pathway, activated (A)PC, not only has anticoagulant, but also anti-inflammatory, anti-apoptotic and other cytoprotective properties  . Evidence indicates that the activity of the PC system is impaired in the lungs of patients with pneumonia, as reflected by reduced bronchoalveolar levels of PC and APC , . Downregulation of the PC pathway has been correlated with disease severity and mortality in pneumonia and sepsis , . Importantly, intravenous infusion of recombinant human (rh-)APC for  days has been shown to improve survival of patients with severe sepsis  ; the beneficial effect of rh-APC in this trial appeared especially prominent in patients with severe sepsis due to pneumococcal pneumonia  . In line with the above mentioned landmark clinical trial with rh-APC  , we recently found that treatment with recombinant murine (rm-)APC, started  hours after infection in concurrence with antibiotics, improved survival in murine pneumococcal pneumonia as compared to antibiotic treatment alone  . Whereas rm-APC in this study effectively attenuated pulmonary activation of coagulation, it did not exert detectable anti-inflammatory effects in the lungs. Several studies have indicated that early identification and treatment of patients with severe sepsis using standard supportive care improves outcome  . Also, earlier treatment with rh-APC in severe sepsis, i.e. instigated within  hours after organ failure, improves outcome as compared to later treatment , . erefore, in the current study we argued that the administration of rm-APC early in the course of experimental pneumococcal pneu-monia might exert anti-inflammatory effects as opposed to later treatment. us, we administered rm-APC  hours after infection with S. pneumoniae via the airways and in depth examined the effects of therapeutic rm-APC on pulmonary coagulopathy and inflammation using a combination of readouts, including assays for activation of coagulation, a multiplex protein assay measuring  mediators implicated in inflammation, semi-quantitative histopathology and quantitative bacterial cultures of lungs and distant body sites. We here show that therapeutic rm-APC exerts not only anticoagulant but also various anti-inflammatory effects in the lungs in a clinically relevant mouse model of CAP with S. pneumoniae when administered early after infection.
Materials and methods

Animals
Male CBL/ mice were purchased from Charles River (Maastricht, the Netherlands). Mice of  weeks old were used in all experiments. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Amsterdam (DIX ).
Experimental infection and treatment
Pneumonia was induced by intranasal inoculation with ×  colony forming units (CFU) of S. pneumoniae serotype  (American Type Culture Collection, ATCC , Rockville, MD) as described , . Rm-APC and vehicle were obtained from Eli Lilly & Co (Indianapolis, IN)  . Rm-APC and vehicle were diluted in sterile pyrogen-free isotonic saline. Two groups of mice (n = ) were treated  hours after infection with either rm-APC ( μg in  μL) or vehicle ( μl) intraperitoneally and sacrificed after  hours of infection after anesthetizing with ketamine (Nimatek®, Eurovet Animal Health, Bladel, e Netherlands) and medetomidine (Domitor®, Pfizer Animal Health Care, Capelle a/d IJssel, the Netherlands). Blood was drawn from the vena cava inferior, anticoagulated with citrate (:), shaken and stored on ice. Blood was centrifuged at g and plasma was snap frozen in liquid nitrogen and stored at -°C until analysis. Lungs were harvested, weighed and homogenized at °C in sterile saline ( times the lung weight) using a tissue homogenizer (Pro , Pro Scientific Inc., Oxford, CT) and processed as described below. Median lung weights (th & th percentile) were , (,-,) mg in vehicle treated animals and , (,-,) mg in rm-APC-treated animals (p = .). Bacterial outgrowth was determined as described earlier , . For measurements in lung tissue, lung homogenates were diluted : with lysis buffer ( mM NaCl,  mM Tris,  mM MgCl  ,  mM CaCl  ,  (v/v) Triton X-, pH .) with protease inhibitor mix added (AEBSF (-(-aminoethyl) benzenesulfonyl fluoride), EDTA-Na  , Pepstatin and Leupeptin, all from MP Biomedical) and incubated for  minutes on ice, followed by centrifugation at g for  minutes. Supernatants were stored at -°C until analysis.
Assays
Levels of thrombin-antithrombin complexes (TATc) and D-dimer in lung homogenates and plasma were measured by ELISA (TATc: Behringwerke AG, Marburg, Germany; D-dimer: Asserachrom D-dimer, Roche, Woerden, the Netherlands). Plasminogen activator inhibitor type- antigen (PAI-) was measured by ELISA  and plasminogen activator activity (PAA) was determined by an amidolytic assay  . Myeloperoxidase (MPO; HyCult Biotechnology, Uden, the Netherlands), interleukin (IL)-β, keratinocyte-derived chemokine (KC) and macrophage inflammatory protein (MIP)- (all R&D systems, Minneapolis, MN) were measured by ELISA. Levels of cytokines, chemokines, growth factors, haematopoietic factors, acute phase reactants and damage markers (for complete list see tables) were measured by multiplex assay (Rodent Multi-Analyte Profiling, Rules-Based Medicine, Austin, TX).
Histology and immunohistochemistry
e right lung was fixed in  formaline/PBS at room temperature for  hours and embedded in paraffin. Sections of  μm were cut, stained with haematoxylin and eosin and analyzed by a pathologist who was blinded for groups. To score lung inflammation and damage, the entire lung was analyzed with respect to the following parameters: bronchitis, interstitial inflammation, oedema, endothelialitis, pleuritis and thrombus formation. Each parameter was graded on a scale of  to  (: absent, : mild, : moderate, : severe, : very severe). e total histopathological score was expressed as the sum of the scores for the different parameters.
Granulocyte staining was performed using fluorescein isothiocyanate-labeled anti-mouse Ly-G mAb (Pharmingen, San Diego, CA) as described , . Ly-G stained slides were photographed with a microscope equipped with a digital camera (Leica CTR, Leica Microsystems, Wetzlar, Germany). Ten random pictures were taken per slide. Stained areas were analysed with Image Pro Plus (Media Cybernetics, Bethesda, MD) and expressed as percentage of the total surface area.
Statistical analysis
Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation or as medians with interquartiles ranges. Differences between groups were determined with the MannWhitney U test. Analyses were performed using GraphPad Prism version . (GraphPad Software, San Diego, CA, USA). P-values of less than . were considered statistically significant.
Results
Activation of coagulation
To determine the effect of early rm-APC treatment on the local and systemic procoagulant response to murine pneumococcal pneumonia, we infected mice with S. pneumoniae and treated them  hours later with either rm-APC or vehicle. Treatment with rm-APC strongly inhibited local activation of coagulation as shown by decreased levels of TATc and D-dimer  hours post infection in lungs ( Figure  .A and B) of rm-APC treated animals (p < . and < . respectively versus vehicle treated animals). Rm-APC also attenuated coagulation activation in the systemic compartment, as reflected by lower plasma D-dimer levels (p < . versus vehicle) and a trend toward lower plasma TATc concentrations (not significant versus vehicle). Evidence derived from in vitro investigations indicates that APC may stimulate fibrinolysis by inhibiting the main inhibitor of this system, PAI- , . However, rm-APC had no effect on PAI- levels and PAA in either lung homogenates or plasma (not shown).
A.
B. 
Pulmonary and systemic inflammation
Pneumococcal pneumonia was associated with pulmonary inflammation and damage as evidenced by the occurrence of bronchitis, interstitial inflammation, oedema and endothelialitis ( Figure concentrations, indicative for the number of neutrophils in lung tissue, were similar in both groups (Table  .).
To further investigate the effect of rm-APC treatment on the inflammatory response, we determined levels of various cytokines, chemokines, growth factors, haematopoietic factors, acute phase reactants and damage markers in lung homogenates and plasma obtained  hours after infection. Rm-APC treatment was associated with lower levels of many pulmonary cytokines and chemokines (Table .); more specifically, rm-APC as compared to vehicle significantly lowered lung levels of interferon (IFN)-γ, interleukin (IL)-, IL-, IL-, IL-, IL-p, oncostatin-M, . CCL / CXCL = chemokine from subfamily "CC" and "CXC", respectively, EGF = epidermal growth factor, FGF = fibroblast growth factor, GM-CSF = granulocyte macrophage-colony stimulating factor, GST-α = glutathione S-transferase, IFN = interferon, IL = interleukin, LIF = leukemia inhibitory factor, MIP = macrophage inflammatory protein, MMP = matrix metalloproteinase, MPO = myeloperoxidase, OSM = oncostatin-M, SCF = stem cell factor, TF = tissue factor, TIMP = tissue inhibitor of metalloproteinase, TNF = tumor necrosis factor, TPO = thrombopoietin, VCAM = vascular cell adhesion molecule, VEGF = vascular endothelial cell growth factor, vWF = von Willebrand factor.
TNF-α, CCL-, CCL-, CCL-, CCL-, CXCL- and XCL-. Moreover, rm-APC lowered CD and von Willebrand factor. In contrast, rm-APC did not have an effect on plasma levels of these inflammatory markers; rm-APC treatment only induced a modest rise in plasma CCL- and vWF levels (data not shown).
Bacterial outgrowth
To investigate the effect of rm-APC on bacterial outgrowth and dissemination in pneumococcal pneumonia, we determined bacterial loads in lungs, blood and spleen  hours after infection. Rm-APC treatment did not have an effect on bacterial outgrowth in lung, blood or spleen ( Figure  .A-C). C. 
Discussion
Treatment with rh-APC reduces mortality in patients with severe sepsis  . In particular patients with pneumococcal pneumonia as the primary source of infection have been found to benefit from rh-APC  . It has been argued that rh-APC improves sepsis outcome by a combined inhibitory effect on both coagulation and inflammation. Indeed, sepsis patients treated with rh-APC not only displayed reduced activation of coagulation, but also evidence for attenuated inflammation  . Moreover, in several preclinical models APC exerted concurrent anticoagulant and anti-inflammatory effects in not only the systemic but also the pulmonary compartment , . Nonetheless, attempts to unequivocally demonstrate anti-inflammatory effects of exogenous APC in the lung during pneumonia have been elusive ,, . We recently found that treat-ment with rm-APC, started  hours after infection, effectively attenuates pulmonary activation of coagulation and improves survival in pneumococcal pneumonia; the profoundly beneficial effects of rm-APC on coagulation and survival were, however, not paralleled by a detectable effect on lung inflammation  . Previously, it had been shown that early treatment with rh-APC in severe sepsis improves outcome as compared to later treatment , . is led us to hypothesize that APC treatment might have to be initiated early after induction of pneumonia to produce a detectable antiinflammatory effect. We here show for the first time that therapeutic rm-APC, when administered early (after  hours) in pneumococcal pneumonia, not only inhibits pulmonary and systemic activation of coagulation, but also attenuates the production of many inflammatory proteins in lung tissue.
e current study confirms and extends previous investigations that documented the capacity of systemic APC administration to inhibit coagulation activation in the lungs after administration of lipopolysaccharide (LPS)
 , viable bacteria , or influenza A virus  via the airways. Of note, however, in earlier studies in which APC administration was found to attenuate pulmonary coagulopathy during bacterial or viral pneumonia, this treatment did not impact on lung inflammation ,,, . In contrast, in the present study rm-APC exerted a broad inhibitory effect on the production of proteins involved in the regulation of inflammation. One dose of rm-APC administered  hours after induction of pneumonia lowered pulmonary levels of  of  inflammatory proteins in lung tissue, significantly so for the proinflammatory cytokines TNF-α, IFN-γ, IL-p and oncostatin-M, the T helper  cytokine IL-, the hematopoietic cytokines IL-, IL- and IL- and the chemokines CCL-, CCL-, CCL-, CCL-, CXCL- and XCL-. Very recently, we used the same multiplex inflammatory protein assay to determine the impact of more delayed rm-APC administration (i.e.  hours after infection) on lung inflammation during pneumococcal pneumonia  . In that study we did not detect significant alterations in inflammatory mediator levels in the lungs of rm-APC treated mice, either in the presence or absence of antibiotic therapy  . Since the sole difference between the current study and our recent study in murine pneumococcal pneumonia is the timing of rm-APC therapy (i.e.  hours instead of  hours after infection), these data suggest that in later stages of the disease APC loses its capacity to influence lung inflammation while still able to inhibit coagulation. Possibly, the potency of APC is not sufficient to exert an anti-inflammatory effect in the presence of high bacterial loads (providing a stronger proinflammatory stimulus than early after infection). Conceivably, higher APC doses might be able to inhibit pulmonary inflammation even late in the course of pneumonia. However, the APC doses used here resulted in plasma levels that were in the same range as those achieved by continuous intravenous infusion in septic patients , .
Higher doses would be less clinically relevant and, potentially, be associated with a bleeding tendency. In this respect, investigations examining the effects of mutant forms of APC with reduced anticoagulant but enhanced cytoprotective properties in models of severe pneumococcal pneumonia would be of considerable interest - . Such studies could also provide more information into the question whether the anti-inflammatory effects as observed in our study are secondary to anticoagulant or merely direct anti-inflammatory effects.
e fact that our group previously was unable to demonstrate anti-inflammatory effects of APC pretreatment in bacterial pneumonia in rats could be related to the fact that we here used species specific APC, that the timing of APC administration was different from other studies and that we measured a large array of mediators that were not determined in our earlier studies , . In accordance with the current results, intravenous APC reduced pulmonary levels of TNF-α, IL- and several chemokines in rodent models of sterile lung injury induced by acid aspiration  or intratracheal administration of elastase  . Further evidence that APC can inhibit pulmonary cytokine and chemokine production comes from a study in which intravenous APC diminished lung levels of TNF-α, IL- and CCL- in rats with polymicrobial abdominal sepsis  and from a murine lung LPS-study  . In this respect it should be noted that APC can downregulate nuclear factor-κB expression which could impact on the levels of numerous cytokines - . Remarkably, rm-APC diminished the levels of both the prototypic T helper  cytokine IFN-γ and the prototypic T helper  cytokine IL-, further supporting the notion of a general inhibitory effect of this compound on cytokine production during pneumococcal pneumonia. In contrast, in a murine model of allergic airway inflammation inhaled APC selectively inhibited the production of T helper  cytokines, including IL-, while enhancing IFN-γ release  . e fact that rm-APC indeed inhibited IFN-γ production in our model is supported by the finding that rm-APC also reduced the levels of IL-p (a main inducer of IFN-γ) and CXCL (a chemokine produced by various cell types in response to IFN-γ). Clearly, the routes of APC administration (inhaled versus systemic) and the type of inflammation (allergic in a pre-sensitized host versus primary bacterial) differed between this earlier and the present study, which at least in part may explain the discrepant results.
Previous studies on the effects of APC on neutrophil recruitment into the lungs are inconsistent. Intravenous APC inhibited neutrophil influx into the lungs in acid aspiration or elastase induced lung injury in rodents , ; in addition, APC decreased influx of neutrophils into the bronchoalveolar space of healthy humans challenged intrabronchially with LPS  . In contrast, APC did not impact on neutrophil counts in bronchoalveolar lavage fluid of rats with pneumonia caused by S. pneumoniae or P. aeruginosa , , whereas in one study APC even augmented neutrophil influx during P. aeruginosa pneumonia  . e present results, revealing no influence of rm-APC administered  hours after induction of pneumococcal pneumonia, are in line with our earlier findings in rats treated with rh-APC prior to induction of bacterial pneumonia , and in mice treated with rm-APC  hours after induction of pneumococcal pneumonia  . ese earlier studies also did not show an effect of APC on lung histopathology induced by pneumonia , , resembling the current findings. From our study, we can not preclude that at later time points rm-APC would indeed have an impact on neutrophil recruitment. Indeed, a limitation of our study is that only one treatment schedule and one time point for measurements were used. For this reason, the impact of rm-APC on outcome parameters during later phases of pneumococcal pneumonia cannot be discerned from the current investigation. In addition, we did not study the effect of rm-APC therapy in the context of antibiotic treatment (such as was done in our previous manuscript on the effect of rm-APC during pneumococcal pneumonia)
 . We argued that cotreatment with antibiotics at such an early stage would result in a strong inhibition of cytokine/chemokine production due to rapid killing of the then still relatively low bacterial load, making it difficult to detect a potential anti-inflammatory effect of rm-APC.
We studied only one time point after infection. Our investigation therefore does not provide insight into the duration of the anti-inflammatory effect of a single rm-APC dose. In addition, we did not determine the impact of a single rm-APC dose on survival; we considered this of less relevance since APC will not be administered without antibiotics in a clinical setting and in light of our previous study showing that rm-APC given concurrently with ceftriaxone does improve survival in this model  . Notably, the current study should be considered as an extension of our previous data  and as a proof-of-principle that rm-APC is in itself able to exert anti-inflammatory properties in the lungs during pneumococcal pneumonia, when administered at an appropriate time point. As such this study is the first to document anti-inflammatory effects of APC therapy in a model of bacterial pneumonia.
Conclusions
We here show that rm-APC, when administered early after infection, not only inhibits systemic and pulmonary coagulation activation in murine pneumococcal pneumonia but also exerts a broad inhibitory effect on the local production of many different proteins implicated in the regulation of inflammation.
